Cizzle Biotechnology Share Price. CIZ - Stock Quote, Charts, Trade History, Share Chat, Financials. Cizzle Biotechnology Holdings Plc

Gold vs US Dollar

Home
Investing
Stocks
UK
LSE
Cizzle Biotechnology Holdings Plc (CIZ)
Cizzle Biotechnology Holdings Plc (CIZ) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Cizzle Biotechnology Holdings Plc	LSE:CIZ	London	Ordinary Share	GB00BNG2VN02	ORD 0.01P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	2.325	590,327	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
2.30		2.35	2.325	2.325	2.325

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Lighting Equipment, Nec	0.00	-3.92	-1,549.80	-	8.07

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
15:41:13	O	5,000	2.323	GBX

Related Shares
Astrazeneca (AZN), Gsk (GSK), Fusion Antibodies (FAB), Yourgene Health (YGEN)

Cizzle Biotechnology (CIZ) Latest News

Cizzle Biotechnology News

Date	Time	Source	Headline
15/5/2023	21:10	ALNC	TRADING UPDATES: Online Blockchain keeping ADVFN at "arms length"
15/5/2023	13:42	UKREG	Cizzle Biotechnology Holdings PLC Update on Royalty Sharing Agreement in..
27/4/2023	17:02	ALNC	TRADING UPDATES: Ceiba net asset value down, up for Asia Dragon Trust
27/4/2023	07:00	UKREG	Cizzle Biotechnology Holdings PLC Results for the year ended 31 December..
24/4/2023	09:34	ALNC	Cizzle extends partnership with York University for cancer research
24/4/2023	07:00	UKREG	Cizzle Biotechnology Holdings PLC New Research Agreement with the..
30/3/2023	11:05	UKREG	Cizzle Biotechnology Holdings PLC Second Price Monitoring Extn
30/3/2023	11:00	UKREG	Cizzle Biotechnology Holdings PLC Price Monitoring Extension
17/3/2023	16:35	UKREG	Cizzle Biotechnology Holdings PLC Price Monitoring Extension
13/3/2023	09:00	UKREG	Cizzle Biotechnology Holdings PLC Price Monitoring Extension

More Cizzle Biotechnology News

Cizzle Biotechnology Investors Cizzle Biotechnology Takeover Rumours

Cizzle Biotechnology (CIZ) Discussions and Chat

Cizzle Biotechnology Forums and Chat

Date	Time	Title	Posts
25/5/2023	15:02	Cizzle Biotechnology Holdings PLC	1,588
24/1/2023	15:10	Cizzle Biotech	469

Add a New Thread

Cizzle Biotechnology (CIZ) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2023-05-31 14:41:14	2.32	5,000	116.15	O
2023-05-31 14:38:09	2.33	5,000	116.25	O
2023-05-31 12:19:31	2.30	9,212	211.92	O
2023-05-31 11:38:34	2.31	107,404	2,475.66	O
2023-05-31 11:16:32	2.31	10,000	230.50	O

View all Cizzle Biotechnology trades in real-time

Cizzle Biotechnology (CIZ) Top Chat Posts

Top Posts
Posted at 22/3/2023 09:22 by oapknob1 Sooner MURF and Conduit conclude the merger and NASDAQ listing the better for underpinning CIZ share price at these levels. Read Full Thread Follow Reply
Posted at 16/3/2023 16:14 by oapknob1 They get £3,250,000 worth of shares at $10 per share on Conduit listing if they exercise the put option. (Guessing they will instead of waiting on clinical trials, FDA approval then commercialisation of Conduits drug)IF the NASDAQ listing share price goes to $15 or $20 CIZ make more profit depending on price they sell the put option shares at. Read Full Thread Follow Reply
Posted at 16/3/2023 15:46 by smithie6 RNS "09/09/2021 7:00am UK Regulatory (RNS & others) TIDMCIZ RNS Number : 1857L 9 September 2021 Cizzle Biotechnology Holdings Plc Encouraging progress on collaboration with St George Street Capital St George Street Capital announces results of the Phase II ARCADIA study of AZD1656 in diabetic patients with COVID-19 Cizzle Biotechnology, the UK based diagnostics developer, is pleased to provide an update on its collaboration with St George Street Capital ("SGSC"), the UK-based biomedical charity. As announced on 22 June 2021, Cizzle Biotechnology signed a Memorandum of Understanding ("MoU") with SGSC covering a proposed collaboration between the parties to develop a companion diagnostic platform for which Cizzle Biotechnology will receive fees of up to GBP1 million. Further, under the MoU, SGSC has agreed to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street Capital's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of the companion diagnostic. SGSC has today announced the results of the ARCADIA trial; a phase II, randomised, double-blind, placebo-controlled clinical trial in 153 patients to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The initiation of the ARCADIA trial was the result of an existing collaboration between SGSC and AstraZeneca as part of its Open Innovation Programme and it was funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme. SGSC reported there are no safety concerns raised regarding the use of AZD1656 in this patient population and they confirmed that there were strong trends in favour of AZD1656 with respect to mortality. The data from the ARCADIA trial supports continued investigation of AZD1656 for the treatment of diabetics with COVID-19 and in light of these encouraging results, St George Street Capital will undertake commercial discussions with potential licencees and/or fundraise for further clinical trials to investigate AZD1656 in a larger study. Following signature of the MoU, Cizzle Biotechnology expects to enter into a full commercial contract in due course. Whilst any royalty payments to Cizzle Biotechnology are contingent on the successful development of AZD1656, today's announcement by SGSC on the positive results from its clinical trial is significant step forward in Cizzle Biotechnology realising the full potential of its royalty rights in AZD1656. Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We congratulate St George Street Capital on the success of its ARCADIA clinical trial. This further supports our longer-term ambitions to work closely with St George Street Capital and to leverage the technology and know-how of Cizzle Biotechnology to match diagnostic capabilities with therapeutic need. This will increase product opportunities and potential revenue streams for the Company, in addition to our core focus on developing our blood test for the early detection of a majority of the different forms of lung cancer." Commenting, Professor John Martin of UCL, Chairman of SGSC, said: "The completion of ARCADIA marks a significant milestone in the history of the charity St George Street Capital. We have demonstrated our ability to rapidly deliver a clinical trial in an area of unmet clinical need, thus fulfilling our mission to accelerate the development of new treatments for people who need them. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge." Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) ......." Read Full Thread Follow Reply
Posted at 16/3/2023 15:22 by smithie6 there is a 3rd RNS about CIZ & deals with Conduit/SGSA 14th Feb. 2022 Cizzle Biotechnology Holdings PLC 14 February 2022 This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014 which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK MAR") . Upon the publication of this announcement this inside information is now considered to be within the public domain. 14 February 2022 Cizzle Biotechnology Holdings Plc ("Cizzle Biotechnology", "Cizzle" or the "Company") Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has entered into a definitive agreement (the "Agreement") with Conduit Pharmaceuticals Limited ("Conduit") and St George Street Capital Limited ("SGSC") to acquire a 5% economic interest in the commercialisation of the AZD 1656 asset or other such assets being developed by Conduit or SGSC to treat inflammatory pulmonary and cardiovascular disease (the "Economic Interest"). Highlights -- Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022 -- The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021 -- SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussions with multiple pharmaceutical companies about licensing opportunities for AZD 1656 for Covid-19 and potentially for further indications -- The Agreement supports the Company's ambitions to expand its target customer base into the pharmaceutical industry and is in line with its strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets Allan Syms, Executive Chairman of Cizzle Biotechnology, said "The agreement announced today represents an important extension to our close relationship with SGSC and Conduit. On 20 September 2021 we announced we had acquired a stake in SGSC's AZD 1656 asset, providing the opportunity for the Company to receive royalty payments of up to GBP5 million and shortly after SGSC contracted the Company to develop an associated companion diagnostic test for which we will receive fees of up to GBP1 million. "We are now pleased to have the opportunity to increase our stake by an additional 5% in AZD 1656, but significantly the Economic Interest will be uncapped. This new Agreement supports the Company's ambitions to expand its target customer base in the pharmaceutical industry and through a strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets significantly increase shareholder value." Background SGSC is a UK-based medical-charity led by a group of highly decorated academics and ex-pharma executives formed to deliver much needed treatments to patients. SGSC's strategy is to take clinical-ready assets from pharmaceutical companies and to progress them through Phase II medical trials, before licensing them on for Phase III trials and commercialisation in order to create a return for investors and the charity alike. SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussion with multiple pharmaceutical companies about licensing opportunities for AZD 1656 in both Covid-19 and potentially in further indications. Conduit is the exclusive funding partner to the Charity. The ARCADIA trial data, that treated inflammatory pulmonary and cardiovascular disease caused by Covid-19, showed a strong trend towards reduced mortality in patients receiving AZD 1656. The strong trend to improved mortality for patients on AZD 1656 was observed on top of patients receiving other medication as part of standard of care. AZD 1656 was also shown to be well-tolerated in this patient population with no serious adverse reactions (SARs) occurring. Overall, no safety concerns were identified regarding the use of AZD 1656 in this patient population. Furthermore, SGSC has shown there was a significant increase in the migration of the Regulatory T Cells ("Tregs") from the patients who had taken the drug compared to the Tregs from the patients who had not. Tregs are a specialised subpopulation of T cells that act to suppress immune response and combat damaging cells, potentially reducing serious cardiovascular and lung diseases which are causative in the development of lung cancer, which Cizzle is developing its diagnostic test to identify. Under the Agreement Cizzle Biotechnology will receive 5% of all such sums received by SGS pursuant to any AstraZeneca ("AZ") commercialisation or sub-license commercialisation of the AZ asset in inflammatory pulmonary and cardiovascular diseases, after the deduction of certain sums. Consideration for the Agreement Under the terms of the Agreement, Cizzle will pay consideration of GBP1.88 million to SGS for the Economic Interest. Of the consideration payable, GBP1.0 million (the "Initial Consideration") will be satisfied by the issue of 25,000,000 new ordinary shares in the Company (the "Consideration Shares"), at a price of 4.0 pence per Consideration Share, being a premium of 56.9 per cent. to the Company's closing mid-market price of 2.55 pence on 11 February 2022. The remaining consideration of GBP880,000 will be payable in new ordinary shares in the Company issued at 4.0 pence per share, on the sooner of receiving shareholder approval to issue the shares or the first anniversary of completion. Total Voting Rights On completion of payment of the Initial Consideration, Conduit will hold 25,000,000 ordinary shares in Cizzle representing 8.98 per cent. of the issued share capital of the Company, as enlarged by the issue of the Consideration Shares. The Company has applied for admission of the 25,000,000 Initial Consideration new Ordinary Shares to trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective on or around 17 February 2022. The Company's issued ordinary share capital on Admission will consist of 278,447,788 ordinary shares of 0.1 pence each, all with voting rights. The Company holds no ordinary shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) Allenby Capital Limited +44(0) 20 33285656 John Depasquale Alex Brearley Novum Securities Limited +44(0) 20 7399 9400 Colin Rowbury Jon Bellis IFC Advisory Limited +44(0) 20 3934 6630 Tim Metcalfe cizzle@investor-focus.co.uk Florence Chandler Notes to Editors: About Cizzle Biotechnology...... END Read Full Thread Follow Reply
Posted at 16/3/2023 14:55 by smithie6 ...my crystal ball says that these shares will be placed in the acquistion of Conduit by nasdaq:MURF.... giving CIZ £3.25 million in cash, a profit of ~ £1.15 million....but a cash lump of ~£3.25 million ( if CIZ reports some profit in an accounting period then it can balance that off against costs such as its own costs & money paid to cos. doing development work for CIZ) £3.25 million would/will be very helpful for CIZ which currently has no sales income....& also avoid dilution. Read Full Thread Follow Reply
Posted at 16/3/2023 14:38 by oapknob1 19 December 2022Cizzle Biotechnology Holdings plc("Cizzle" or the "Company")Put Option for Sale of Economic Interest and Royalty Sharing Agreement in AZD1656Subscription to raise net proceeds of GBP115,586 at 1.6p per shareCizzle Biotechnology Holdings plc, the UK based diagnostics developer, is pleased to announce that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat inflammatory pulmonary and cardiovascular disease (the "Economic Interest"); and (ii) its royalty sharing agreement with St George Street Capital ("SGSC"), the UK-based biomedical charity (the "Royalty Sharing Agreement') to Conduit Pharmaceuticals Limited ("Conduit") for a total consideration of GBP3.25 million to be satisfied through the issuance of new shares in Conduit (the "Option").The Economic Interest and Royalty Sharing Agreement were valued at cost, totalling GBP2,080,000, in the Company's 2022 interim results to 30 June 2022, announced on 28 September 2022. No profits or revenues were attributable to the assets subject to the Option. The Option is exercisable solely at the discretion of Cizzle and Cizzle has agreed to pay Conduit GBP120,000 in cash as the premium for the Option, which has a nine-month term. Read Full Thread Follow Reply
Posted at 16/3/2023 14:37 by oapknob1 9 November 2022Cizzle Biotechnology Holdings Plc("Cizzle Biotechnology", or the "Company")Conduit Pharmaceuticals Proposed ListingCizzle Biotechnology, the UK-based diagnostics developer, is pleased to note the announcement by Conduit Pharmaceuticals Limited ("Conduit") that they intend to become a publicly traded company on NASDAQ in the USA via a merger with Murphy Cannon Acquisition Corp. ("Murphy"), a NASDAQ listed special purpose acquisition company.Cizzle Biotechnology announced on 29 February 2022 that it has entered into a definitive agreement with Conduit and St George Street Capital Limited ("SGSC") to acquire a further 5% economic interest in the commercialisation of the AZD 1656 asset or other such assets being developed by Conduit or SGSC to treat inflammatory pulmonary and cardiovascular disease, for a total consideration of GBP1.88m, which was paid through the issue of new ordinary shares in the Company at 4.0 pence per share. It has been reported that AZD 1656 acts as an immunomodulator to dampen inflammatory response which could have wider applications in managing serious cardiovascular and lung diseases. Read Full Thread Follow Reply
Posted at 16/3/2023 13:58 by smithie6 contact2fs nasdaq:murf is the ticker for a big shell co. on Nasdaq which is doing the acquisition of Cordiant Pharma....& CIZ owns shares or warrants/options or CLNs in Cordiant. so, when Cordiant backs in to MURF & is listed then CIZ has the chance, if it wants, to sell some/all of its shares (hopefully at a profit) to help fund CIZ, without any new dilution at CIZ. 'if' the deal gives a profit to CIZ it will help give ppl confidence in the boss of CIZ as being a good deal maker; & vice versa if it produces a loss ! Read Full Thread Follow Reply
Posted at 27/2/2023 10:06 by smithie6 Conduit & Ciz. after watching the relevant part of the interview with the chairman, link provided above by coox, thanks. I see that the royalty rights in the Conduit drug in development AZD1656 (which was/is used with Covid patients where the body attacks its own lung cells, which can cause death, I think...& drug suppresses that. A drug in development can be used when its a life/death situation & there are no approved drugs to use that will work) can be converted to shares in Conduit for the value of £3.25 million, which Ciz could sell once Conduit is listed & use to help fund CIZ. (verbal from the chairman in the interview). Is that documented in an RNS ? which one ? 'if' that were to happen it would be a very good return for Ciz & phps more importantly :- - give confidence in the skills of the chairman/company - give confidence in the excellent contacts & mutual respect between the chairman/company & other companies/specialists in the drug development sector. ----- I had some shares in STX (Shield Therapeutics) once ...but then sold as the price drifted lower & because the boss of the co. came across badly in interviews & wasn't well regarded by investors on msg boards. Whereas here at CIZ from the little I have seen of the chairman & the real deals done in a short time, I'm impressed, very good, 9.5/10. I'd never give anyone 10/10, je je ! Read Full Thread Follow Reply
Posted at 27/2/2023 09:34 by smithie6 Conduit, SGSC & CIZ so, CIZ has paid £1.8-1.9 million (all in CIZ shares; all then sold by Conduit/SGSC I think) "5% economic interest in the commercialisation of the AZD 1656 asset or other such assets being developed by Conduit or SGSC to treat" does CIZ have any shares or option for shares in Conduit ?? UPDATE looks like no. but the 5% royalty deal looks like a bargain purchase by CIZ since Conduit say their listed cap. value should be around 700 million $ !! & it is clear that more lung drugs/research are likely from them ...& the CIZ 5% royalty include that. The RNS about Conduit listing mentions that it is backing in to a listed shell, Murphy & it is agreed by the 2 boards. hTTps://uk.advfn.com/stock-market/london/cizzle-biotechnology-CIZ/share-news/Cizzle-Biotechnology-Holdings-PLC-Conduit-Pharmace/89501299 Read Full Thread Follow Reply

Cizzle Biotechnology share price data is direct from the London Stock Exchange

Your Recent History

LSE

CIZ

Cizzle Bio..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230601 05:03:01